TME Pharma N.V. reported earnings results for the full year ended December 31, 2022. For the full year, the company reported net loss was EUR 15.13 million compared to EUR 14.45 million a year ago. Basic loss per share from continuing operations was EUR 12.86 compared to EUR 21.9 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.1666 EUR | -5.23% | -26.12% | -27.57% |
Jun. 19 | TME Pharma: in the red, a broker cuts its target | CF |
Jun. 19 | TME PHARMA : Invest Securities reduces its target | CF |
Chiffre d''affaires - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-27.57% | 5.37M | |
+34.01% | 51.07B | |
+33.84% | 38.86B | |
-8.02% | 38.78B | |
-8.98% | 26.69B | |
+12.56% | 26.35B | |
-19.62% | 19.46B | |
+39.18% | 13.58B | |
+31.47% | 12.46B | |
-3.40% | 11.75B |
- Stock Market
- Equities
- ALTME Stock
- News TME Pharma N.V.
- TME Pharma N.V. Reports Earnings Results for the Full Year Ended December 31, 2022